zofran 8 mg
sandoz a/s - ondansetronhydroklorid - tablett, filmdrasjert - 8 mg
zofran 4 mg
sandoz a/s - ondansetronhydroklorid - tablett, filmdrasjert - 4 mg
zofran 4 mg
sandoz a/s - ondansetronhydroklorid - smeltetablett - 4 mg
zofran 8 mg
sandoz a/s - ondansetronhydroklorid - smeltetablett - 8 mg
zofran 16 mg
novartis norge as - ondansetronhydroklorid - stikkpille - 16 mg
zofran 0.8 mg/ ml
2care4 aps - ondansetronhydrokloriddihydrat - mikstur, oppløsning - 0.8 mg/ ml
zofran 16 mg
orifarm as - ondansetron - stikkpille - 16 mg
zofran 16 mg
orifarm as - ondansetron - stikkpille - 16 mg
zofran 16 mg
orifarm as - ondansetron - stikkpille - 16 mg
vanflyta
daiichi sankyo europe gmbh - quizartinib dihydrochloride - leukemi, myeloid - antineoplastic agents, protein kinase inhibitors - vanflyta is indicated in combination with standard cytarabine and anthracycline induction and standard cytarabine consolidation chemotherapy, followed by vanflyta single-agent maintenance therapy for adult patients with newly diagnosed acute myeloid leukaemia (aml) that is flt3-itd positive.